Tiffany Mullin, MD
Gynecology · Katy, TXNPI 1689610867
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,086 and has fallen 59.2% since, to $443 in 2025.
Across 231 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$657
- Abbott$298
- Bayer$277
- Regeneron Healthcare Solutions, Inc.$264
- Mayne Pharma Commercial LLC$254
- Pfizer$227
- plus $3K from 52 others
What the payments were for
- Food & beverage$4,52797%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$258
- QULIPTA$125
- UBRELVY$125
- Repatha$122
How this compares
$4,646 in reported general payments places this provider in the 85th percentile of 161 gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $862 |
| ValacyclovirValacyclovir Hcl | 15 | $157 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Katy
- Richard FarnamEl Paso$1.2M
- Jessica ShepherdDallas$809K
- Linda LacyEl Paso$627K
- John WhitfieldFort Worth$141K
- Robert ZurawinHouston$61K
- Charles EubankCorpus Christi$51K
- Tiffany JacksonGarland$50K
- Cynthia Chaparro-KruegerAustin$41K
- Laura SheltonCorpus Christi$22K
- Nicolas XydasHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.